- Home
- LVLU vs KRON Comparison
LVLU vs KRON Comparison
Compare LVLU & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- KRON
- Stock Information
- Founded
- LVLU 1996
- KRON 2017
- Country
- LVLU United States
- KRON United States
- Employees
- LVLU N/A
- KRON N/A
- Industry
- LVLU Catalog/Specialty Distribution
- KRON Medicinal Chemicals and Botanical Products
- Sector
- LVLU Consumer Discretionary
- KRON Health Care
- Exchange
- LVLU Nasdaq
- KRON Nasdaq
- Market Cap
- LVLU 66.0M
- KRON 60.3M
- IPO Year
- LVLU 2021
- KRON 2020
- Fundamental
- Price
- LVLU $1.20
- KRON $0.87
- Analyst Decision
- LVLU Hold
- KRON Buy
- Analyst Count
- LVLU 4
- KRON 3
- Target Price
- LVLU $1.58
- KRON $1.63
- AVG Volume (30 Days)
- LVLU 37.3K
- KRON 173.3K
- Earning Date
- LVLU 11-13-2024
- KRON 11-13-2024
- Dividend Yield
- LVLU N/A
- KRON N/A
- EPS Growth
- LVLU N/A
- KRON N/A
- EPS
- LVLU N/A
- KRON N/A
- Revenue
- LVLU $324,699,000.00
- KRON $9,864,000.00
- Revenue This Year
- LVLU N/A
- KRON $52.58
- Revenue Next Year
- LVLU $3.39
- KRON N/A
- P/E Ratio
- LVLU N/A
- KRON N/A
- Revenue Growth
- LVLU N/A
- KRON 146.56
- 52 Week Low
- LVLU $1.02
- KRON $0.69
- 52 Week High
- LVLU $2.84
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- LVLU 39.38
- KRON 44.46
- Support Level
- LVLU $1.39
- KRON $0.84
- Resistance Level
- LVLU $1.79
- KRON $0.88
- Average True Range (ATR)
- LVLU 0.25
- KRON 0.05
- MACD
- LVLU -0.04
- KRON -0.00
- Stochastic Oscillator
- LVLU 2.90
- KRON 41.28
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.